IL316674A - History of Oxoindolinyl Amide for Inhibition of NLRP3 and Its Uses - Google Patents

History of Oxoindolinyl Amide for Inhibition of NLRP3 and Its Uses

Info

Publication number
IL316674A
IL316674A IL316674A IL31667424A IL316674A IL 316674 A IL316674 A IL 316674A IL 316674 A IL316674 A IL 316674A IL 31667424 A IL31667424 A IL 31667424A IL 316674 A IL316674 A IL 316674A
Authority
IL
Israel
Prior art keywords
alkyl
haloalkyl
cycloalkyl
alkoxy
halo
Prior art date
Application number
IL316674A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ventus Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics U S Inc filed Critical Ventus Therapeutics U S Inc
Publication of IL316674A publication Critical patent/IL316674A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/96Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL316674A 2022-05-13 2023-05-12 History of Oxoindolinyl Amide for Inhibition of NLRP3 and Its Uses IL316674A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263341614P 2022-05-13 2022-05-13
PCT/US2023/066934 WO2023220715A1 (en) 2022-05-13 2023-05-12 Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereof

Publications (1)

Publication Number Publication Date
IL316674A true IL316674A (en) 2024-12-01

Family

ID=86760226

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316674A IL316674A (en) 2022-05-13 2023-05-12 History of Oxoindolinyl Amide for Inhibition of NLRP3 and Its Uses

Country Status (15)

Country Link
US (1) US20240368131A1 (enExample)
EP (1) EP4522591A1 (enExample)
JP (1) JP2025516719A (enExample)
KR (1) KR20240172228A (enExample)
CN (1) CN119212978A (enExample)
AU (1) AU2023268557A1 (enExample)
CA (1) CA3251062A1 (enExample)
CL (1) CL2024003460A1 (enExample)
CO (1) CO2024015371A2 (enExample)
IL (1) IL316674A (enExample)
JO (2) JOP20240257A1 (enExample)
MX (1) MX2024013978A (enExample)
PE (1) PE20251252A1 (enExample)
TW (1) TW202409013A (enExample)
WO (1) WO2023220715A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026510921A (ja) * 2023-03-17 2026-04-10 ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド Nlrp3を阻害するためのアミド誘導体及びその使用
WO2025106863A1 (en) * 2023-11-15 2025-05-22 Ventus Therapeutics U.S., Inc. Lactam derivatives for inhibiting nlrp3 and uses thereof
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
UY38687A (es) * 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso

Also Published As

Publication number Publication date
JOP20240257A1 (ar) 2024-11-12
CL2024003460A1 (es) 2025-04-11
MX2024013978A (es) 2024-12-06
JOP20240258A1 (ar) 2024-11-12
KR20240172228A (ko) 2024-12-09
CA3251062A1 (en) 2023-11-16
CO2024015371A2 (es) 2024-12-30
US20240368131A1 (en) 2024-11-07
PE20251252A1 (es) 2025-05-06
EP4522591A1 (en) 2025-03-19
CN119212978A (zh) 2024-12-27
WO2023220715A1 (en) 2023-11-16
AU2023268557A1 (en) 2024-11-14
JP2025516719A (ja) 2025-05-30
TW202409013A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
US12421236B2 (en) Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
MX2022008066A (es) Compuestos triciclicos sustituidos.
RU2004109812A (ru) Ингибиторы цистеинпротеазы 2-циано-4-аминопиримидинового строения с ингибирующим действием на катепсин к для лечения воспалительных и других заболеваний
JP2020510010A5 (enExample)
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
JP7661361B2 (ja) Il-17のモジュレーターとしてのイミダゾピリミジン
EA200501098A1 (ru) Антибактериальные агенты
RU2003105805A (ru) Производные 4-фенилпиридина в качестве антагонистов рецепторов нейрокинина-1
JP2010540508A5 (enExample)
ATE427949T1 (de) 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
RU2006125630A (ru) Дифенилаэетидиноновые производные, обладающие активностью, ингибирующей всасывание холестерина
WO2010042684A4 (en) Pyrrolotriazine kinase inhibitors
WO2022219407A1 (en) Isoindolinone compounds
KR101862041B1 (ko) 그람음성 활성을 갖는 카바페넴 항균제
RU2007147340A (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
EA200201264A1 (ru) 5-хлор-3(4-метансульфонилфенил)-6'-метил-[2,3']бипиридинил в чистой кристаллической форме и способ синтеза
JP2024517765A (ja) インテグリン阻害剤の拡大投与レジメン
JP2025516719A5 (enExample)
JP2025500176A (ja) カルボン酸バイオアイソスタを含むdhodh阻害剤
ZA200210161B (en) Coumarin derivatives with COMT inhibiting activity.
KR20240172228A (ko) Nlrp3을 억제하기 위한 옥소인돌리닐 아미드 유도체 및 이의 용도
AU2001244671B2 (en) Quinolonecarboxylic acid derivative
CA2108356A1 (en) Antibiotic compounds
KR20220053637A (ko) 치환된 우레아 다이하이드로오로테이트 탈수소효소 억제제
CA2534003A1 (en) 3-quinuclidinyl-n-biarylamides as nicotinic acetylcholine receptor agonists